Shalmali Pal | Authors

With Longer Survival Rates, AIDS Patients Face Elevated Cancer Risk

February 22, 2011

Thanks to the widespread use of highly active antiretroviral therapy (HAART), AIDS patients continue to live longer after their initial diagnosis.

Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients

December 30, 2010

Like the protective plastic cap at the ends of shoelaces that prevent them from unraveling, telomeres protect the ends of chromosomes. These small strips of DNA prevent chromosome tips from fraying during cell division. But as the cells divide, the telomeres shorten and the cells age. Shortened telomeres have been linked to an increased risk of cancer development. Researchers at the Mayo Clinic in Rochester, Minn., wanted to see if telomere shortening was linked to colon cancer development at a younger age.

Postgastrectomy Patients May Benefit From HP Eradication Rx

December 29, 2010

After resection for cancer or peptic ulcer disease, the mucosa of the gastric stump is considered prone to the development of gastric cancer precursor lesions (see Fact box), most likely because of exposure to Helicobacter pylori infection. Italian researchers set out to determine if the risk of gastric cancer recurrence was greater in the stump in the presence of HP infection.

ASA404 fails second late-stage lung cancer trial

December 23, 2010

Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.

Best of the Society for Integrative Oncology: 2010

December 22, 2010

NEW YORK-Turkey tail, healing touch, and liquidambar stryraciflua are areas in complementary medicine that are worth keeping an eye on, according to integrative oncology experts. The Society for Integrative Oncology (SIO) named five abstracts as its best during its 2010 meeting.

Industry update: Taxotere-based regimen leads to better survival rates in node-positive early disease

December 13, 2010

Ten-year follow-up results from the BCIRG 001 trial make a case for TAC therapy over FAC. In another study, researchers suggested a link between aromatase inhibitor therapy and breast density.

Dual HER2 blockade with lapatanib, trastuzumab proves valid in two major trials

December 13, 2010

Jose Baselga, MD, PhD, and Michael Untch, MD, shared results from the NeoALLTO and GeparQuinto trials, respectively. NeoALLTO is a phase III, randomized, open-label, neoadjuvant study of lapatinib (Tykerb), trastuzumab (Herceptin), and their combination plus paclitaxel in women with HER2-positive primary breast cancer. GeparQuinto (GBG 44) is evaluating lapatinib vs trastuzumab in combination with neoadjuvant anthracycline- and taxane-based chemotherapy.

CYP2D6 testing falls short as predictor of adjuvant tamoxifen efficacy

December 13, 2010

Researchers from the ATAC and BIG 1-98 trials reported that CYP2D6 testing is not ready for prime time for gauging response to tamoxifen. While of the leading researchers in the field of CYP2D6 genotyping posed some key questions that need to be answered before CYP2D6 can be officially ruled out, or embraced, in clinical practice, these study results strongly suggest that CYPD2D6 testing should not be part of the standard of care, said Claudine Isaacs, MD.

Industry Update: Agents Slow Disease Progression, Improve Daily Function in Metastatic Breast Cancer

December 10, 2010

Results from the GINECO group study demonstrate Afinitor’s ability to buy more time for patients while Xgeva makes everyday life less painful.